Primary chemoablation of recurrent low-grade intermediate-risk non-musical-invasive bladder cancer with UGN-102: results from the phase 3 ENVISION trial

Primary chemoablation with UGN-102 in patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer resulted in a 79.6% CR rate. Patients achieving a CR had an 82.3% likelihood of remaining disease-free 1 year later.